Trial Profile
A Phase 2, Double-Blind, 36-Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis (EE) and Maintenance of Healed EE in Pediatric Subjects Aged 2 to 11 Years With EE
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Aug 2023
Price :
$35
*
At a glance
- Drugs Dexlansoprazole (Primary)
- Indications Erosive oesophagitis
- Focus Therapeutic Use
- Sponsors Takeda; Takeda Development Centre Europe
- 16 Aug 2023 Status changed from not yet recruiting to recruiting.
- 28 Apr 2023 Planned initiation date changed from 31 Mar 2023 to 30 Jun 2023.
- 15 Feb 2023 Planned initiation date changed from 30 Jan 2023 to 31 Mar 2023.